Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0182 • ACR Convergence 2020
Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Spaethling-Mestekemper⁸, Christoph Kuhn⁹, Matthias Englbrecht¹⁰, Wolfgang Vorbrueggen¹¹ and Martin Welcker¹², ¹Rheumatology-Nephrology Practice, Erlangen, Germany, ²Department of Rheumatology, Internal Medicine, Rhein-Maas-Hospital, Wuerselen, Germany, ³Medical Centre Stolberg, Stolberg, Germany, ⁴Practice for Rheumatology and Internal Medicine, Berlin, Germany, ⁵Rheumatology-Nephrology Practice, Erlangen, ⁶Rheumatology Practice, Osnabrueck, ⁷Rheumatology Practice, Osnabrueck, Germany, ⁸Rheumatology Group Practice, Muenchen, Germany, ⁹Rheumatology Practice, Karlsruhe, ¹⁰Freelance Healthcare Data Scientist, Eckental, Germany, ¹¹Foundation for fostering rheumatology, Wuerselen, Germany, ¹²MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany
Background/Purpose: Patient registries have become a common approach to learn from patient-related data by prospectively including large numbers of individuals into a sample followed over…
Abstract Number: 0320 • ACR Convergence 2020
Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients
Tal Gazitt¹, Muhanad Abu Elhija¹, Amir Haddad¹, Idit Lavi¹, Muna Elias¹ and Devy Zisman¹, ¹Carmel Hospital, Haifa, Israel
Background/Purpose: To assess the implementation of the “Treat-to-Target” (T2T) concept using validated composite disease activity scores in daily management of psoriatic arthritis (PsA).Methods: A retrospective…
Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Laure Gossec¹, Jessica Walsh², Kaleb Michaud³, Elizabeth Holdsworth⁴, Steven Peterson⁵, Sophie Meakin⁴, Nicola Booth⁴, Soumya Chakravarty⁶, James Piercy⁴ and Alexis Ogdie⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…
Abstract Number: 0359 • ACR Convergence 2020
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Soumya Chakravarty², Robert McLean³, Taylor Blachley³, Toana Kawashima⁴, Iris Lin⁵, Jonathan Uy⁶, Arthur Kavanaugh⁷ and Alexis Ogdie⁸, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Scientific Affairs, LLC, Horsham, ⁷UC San Diego Health System, San Diego, CA, ⁸Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…
Abstract Number: 0500 • ACR Convergence 2020
Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis
Jessica Walsh¹, Sophie Belman², Courtney Carroll², Michael Milliken², Benjamin Haaland², Kristina Callis Duffin², Gerald Krueger² and Bing-jian Feng², ¹University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are common and impair quality of life and function. The study objective was to identify phenotypes, genetic…
Abstract Number: 0878 • ACR Convergence 2020
Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy
Angela Gupta¹, Sofi Damjanovska², Alyssa Lange³, Brigid Wilson⁴, Taissa Bej⁴, Maya Mattar⁵, David Zidar⁶ and Donald Anthony⁷, ¹(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ³Case Western Reserve University, Cleveland, ⁴Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁵Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ⁶Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁷Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Absolute lymphocyte count (ALC) is a parameter that represents the number of lymphocytes (B, T, and NK cells) in the blood, and lymphopenia often…
Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Iain McInnes¹, Philip Mease², Dafna Gladman³, Laura Coates⁴, Peter Nash⁵, Alexis Ogdie⁶, Frank Behrens⁷, Philippe Goupille⁸, Arthur Kavanaugh⁹, Ruvie Martin¹⁰, Erhard Quebe-Fehling¹¹ and Corine Gaillez¹¹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Oxford, Oxford, United Kingdom, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸CHU Tours, department of rheumatology, Tours, France, ⁹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
Abstract Number: 1336 • ACR Convergence 2020
Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
Eric Toussirot¹, Renaud Winzenrieth², Maxime Desmarets³, Daniel Wendling⁴, Francois Aubin⁵ and Gilles Dumoulin⁶, ¹CIC biotherapies, Besançon University Hospital, Besançon, France, ²GALGO medical, Barcelona, Spain, ³INSERM CIC-1431, Besancon, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Dermatology, Besancon, France, ⁶Laboratoire de Biochimie Médicale, UF de Biochimie Endocrinienne et Métabolique, Besancon, France
Background/Purpose: current data regarding areal bone mineral density (aBMD) in patients with psoriasis (PsO) or psoriatic arthritis (PsA) are conflicting. Results on Trabecular Bone Score…
Abstract Number: 1368 • ACR Convergence 2020
Proportions of Patients Achieving a Minimal Disease Activity State upon Treatment with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study
Peter Nash¹, Michael Luggen², Ferran J. García Fructuoso³, Richard Chou⁴, Alan Mendelsohn⁵, Stephen Rozzo⁵ and Iain McInnes⁶, ¹School of Medicine Griffith University, Brisbane, Queensland, Australia, ²University Hospital/University of Cincinnati College of Medicine, Cincinnati Rheumatic Disease Study Group, Inc, Cincinnati, OH, ³Hospital CIMA Sanitas, Barcelona, Spain, ⁴University at Buffalo, School of Medicine and Biomedical Sciences, Amherst, NY, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved in the US, EU, and Australia to treat moderate to severe plaque psoriasis.1 A randomized,…
Abstract Number: 1771 • ACR Convergence 2020
Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Review and Meta-analysis
Sabrina Hamroun¹, Aghilès Hamroun², Jean-Joël Bigna³, Frauke Foerger⁴, Edem Allado⁵ and Anna Molto¹, ¹Rheumatology Department, Cochin Hospital, Paris, Paris, France, ²Lille University, Faculty of Medicine, Lille, France, Lille, France, ³School of Public Health, Faculty of Medicine, University of Paris Sud XI, Le Kremlin-Bicêtre, France, Paris, France, ⁴University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland, ⁵Rheumatology Department, University Hospital of Nancy, France, Nancy, France
Background/Purpose: Women with spondyloarthritis (SpA) are often affected by the disease during their reproductive years1. However, little is known about the impact of the disease…
Abstract Number: 0305 • ACR Convergence 2020
A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis
Rebecca Haberman¹, Lourdes Perez-Chada², Vinod Chandran³, Cheryl Rosen⁴, Christopher Ritchlin⁵, Lihi Eder⁶, Philip Mease⁷, Soumya Reddy⁸, Alexis Ogdie⁹, Joseph Merola¹⁰ and Jose Scher¹, ¹NYU School of Medicine, New York City, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁶Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁸NYU School of Medicine, New York, NY, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The concept of prevention of psoriatic arthritis (PsA) has gained increased interest given the physical limitation and poor quality-of-life experienced by PsA patients coupled…
Abstract Number: 0321 • ACR Convergence 2020
Outcome Measures in Psoriatic Arthritis Registries Are Very Heterogeneous: A Systematic Literature Review of 27 Registries, or 16183 Patients
Krystel Aouad¹, Georgia Moysidou¹, Antsa Rakotozafiarison¹, Bruno Fautrel² and Laure Gossec¹, ¹Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ²Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Psoriatic arthritis (PsA) is a multidimensional inflammatory disease for which multiple outcome measures can be used, to assess disease activity e.g. through composite scores,…
Abstract Number: 0338 • ACR Convergence 2020
Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis
Eugenia Chen¹ and Maida Wong², ¹Department of Medicine, University of California Irvine, Orange, CA, ²Division of Rheumatology, Department of Medicine, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that involves musculoskeletal and skin manifestations. Such autoimmune disease has been associated with increased lymphoproliferative disease…
Abstract Number: 0360 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Several studies have shown an negative association between smoking status and psoriatic arthritis (PsA) clinical outcomes1,2. The German non-interventional study AQUILA provides real-world data…
Abstract Number: 0501 • ACR Convergence 2020
Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis – A Prospective Cohort Study
David Simon¹, Koray Tascilar¹, Arnd Kleyer¹, Sara Bayat², Eleni Kampylafka², Axel Hueber³, Juergen Rech¹, Louis Schuster¹, Klaus Engel⁴, Michael Sticherling² and Georg Schett⁵, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ⁴Siemens Healthcare GmbH Digital Technology & Camp; Innovation, SHS DS DTI, Erlangen, Germany, ⁵Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: We have previously reported that the presence of musculoskeletal pain in psoriasis patients is associated with a higher risk of developing psoriatic arthritis (PsA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].